While the 2020 patent expiration on Marquibo is an issue, FDA approval will grant Spectrum exclusivity for that indication (and the reimbursement that goes with it) for seven years from the start of sales, I believe., or is it longer than that?
Captisol enabled drugs will replace all of the propylene glycol co-solvated drugs due to far superior safety profile and the enhanced stability it provides. The FDA is accepting captisol NDAs ASAP - Lundbeck today, Spectrum soon:
"Captisol® licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine."
The lack of premarket sales after last nights indifferent aftermarket suggests to me that we will have a brief short attack during the first trading hour followed by a slight recovery as long term investors gather cheap shares. This pattern occurred last Friday with ELGX which is now recovering. Clearly, the trader/posters on this MB are currently pushing.
You're over thinking, trying to guess what traders will do. The company is building its base and the negativity has already been baked into the current price. Even if there are no surprises, from what is already known, I doubt there will be more than a brief sell off tomorrow, if at all.
Agreed, last day of the month window dressing exacerbated by the anticipated dump after earnings on Friday.
The company was incorporated in California in March 1992
under the name Cardiovascular Dynamics, Inc. and
reincorporated in Delaware in
June 1993. In January 1999, we merged with privately held Radiance Medical
Systems, Inc. and changed our name
to Radiance Medical Systems, In
c. and in May 2002, we
merged with privately
held Endologix, Inc., and changed our name to Endologix, Inc.
By their own admission in yesterdays CC, the current quarter will be disappointing as well, in part due to competition from Cook and reduced sales at non-clinical trial centers. Traders pounce on such weakness, though I do believe the stock will recover by this time next year.
placing wells closer together to more fully drain the best ground that lies in between.
CEMI already has a product placement with RVR. In July, they licensed CEMI technology for the development of a rapid dengue fever test to be produced and distributed throughout Asia. An extension of this relationship to other tests seems natural.
These live demos at medical conferences are very persuasive. This is how ELGX successfully broke into the AAA market several years ago.
Dr. Rodriguez commented, "The VELA delivery system is very intuitive and the endograft has excellent visibility. Our early experience has been very positive and we are planning to use the VELA Proximal Endograft in a live EVAR procedure on February 12, 2014 at the iCON meeting in Phoenix, Arizona." iCON is the International Congress on Endovascular Interventions, a well attended medical meeting for vascular specialists from around the world.
Before the run up above $10. we turned when the low dropped below the previous 8.24 200 day moving average, We're well below that now and I don't believe we'll enter the sevens given all the positive signs that abound.
Last years Q4 was released on February 21, 2013, that's nearly a month away. Other than speculation, I don't see real news for the next four weeks which puts SPPI in play for further decline during the current contraction.
Belinostat may not be the winner Raj hoped for when he took it under his wing, and that could be why it is not being pursued aggressively as has been observed here, but I don't fault Raj for not knowing beforehand what the trials would reveal. Most trial drugs fail, Belinostat has not. It may still have a payday.